nanaomycin e has been researched along with imiquimod in 1 studies
*Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS. [MeSH]
*Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS. [MeSH]
| Studies (nanaomycin e) | Trials (nanaomycin e) | Recent Studies (post-2010) (nanaomycin e) | Studies (imiquimod) | Trials (imiquimod) | Recent Studies (post-2010) (imiquimod) |
|---|---|---|---|---|---|
| 6 | 0 | 1 | 3,264 | 284 | 1,963 |
| Protein | Taxonomy | nanaomycin e (IC50) | imiquimod (IC50) |
|---|---|---|---|
| Histamine H2 receptor | Homo sapiens (human) | 1.506 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 2.621 | |
| Adenosine receptor A2a | Homo sapiens (human) | 5.32 | |
| 7,8-dihydro-8-oxoguanine triphosphatase | Homo sapiens (human) | 0.646 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Funatsu, T; Harada, Y; Ikoma, K; Matsui, Y; Misawa, T; Nakayama, A; Nishida, S; Noguchi, Y; Pan, Y; Saitoh, T; Shirasaki, Y; Sunazuka, T; Takahama, M; Takemura, N; Taura, M | 1 |
1 other study(ies) available for nanaomycin e and imiquimod
| Article | Year |
|---|---|
Nanaomycin E inhibits NLRP3 inflammasome activation by preventing mitochondrial dysfunction.
Topics: Caspase 1; Imiquimod; Inflammasomes; Interleukin-1beta; Mitochondria; Naphthoquinones; NLR Family, Pyrin Domain-Containing 3 Protein | 2022 |